ProCE Banner Activity

CONTROL: Phase II Trial of Antidiarrheal Prophylaxis or Neratinib Dose Escalation for Neratinib-Associated Diarrhea in Patients With HER2+ Early BC

Slideset Download
Conference Coverage
Structured loperamide prophylaxis reduced the incidence, severity, and duration of treatment-associated diarrhea in patients with HER2+ early breast cancer receiving extended adjuvant neratinib therapy after trastuzumab-based adjuvant therapy.

Released: December 16, 2019

Expiration: December 14, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen